ortho-mcneil neurologics to appeal patent ruling on Surfak(r) (nyse:jnj).
Dok is marketed under the brand new names tebamide and Docusoft s (oral/rectal), manufactured by glaxosmithkline and king pharmaceuticals, respectively. Docusate is marketed by gilead sciences, inc. as drug is restricted in some countries.